Capecitabine: guaranteed access in adjuvant treatment of breast cancer


According to the Summary of Product Characteristics,1 capecitabine is indicated for locally advanced or metastatic breast cancer in combination with docetaxel after cytotoxic chemotherapy has failed (the previous treatment must have included an anthracycline), in monotherapy after taxanes and anthracycline have failed, or for patients for whom continuing with anthracycline treatment is not indicated.

Its adjuvant indication in non-pathological complete response triple-negative breast cancer with residual disease after neoadjuvant therapy and surgery (progression after taxane) was associated with increased …



Source link

Leave A Reply

Your email address will not be published.